Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recilisib
- Development stage
- Unknown
- Lead developer
- Onconova Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous, Intraperitoneal
01
Overview
Recilisib (Ex-RAD) is a small molecule radioprotectant and an activator of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway. Developed by Onconova Therapeutics, it is designed to mitigate the lethal effects of ionizing radiation by promoting cell survival and DNA repair mechanisms. Unlike traditional radioprotectors that act as antioxidants or free radical scavengers, recilisib modulates intracellular signaling pathways to enhance the natural cellular response to radiation-induced damage. It has been investigated in clinical trials for the treatment of acute radiation syndrome (ARS) and is widely used in preclinical research as a pharmacological tool to activate the PI3K/AKT/mTOR axis in various disease models, including cancer, inflammatory disorders, and metabolic conditions.
- Brand names
- Ex-RAD
- Other names
- recilisib sodiumbenzyl 4-sulfamoylphenyl sulfonebenzyl4-sulfamoylphenyl sulfonebenzyl-4-sulfamoylphenyl sulfone
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on recilisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recilisib.